Ulcerative Colitis

Some indicators of suboptimal response included discontinuation of anti-TNF therapy for patients with ulcerative colitis and IBD-related hospitalization for patients with Crohn’s disease.

Barnesiella was positively associated with the first principal component, and category fluency.

The treatment was comparable to darbepoetin alfa in treating patients with chronic kidney disease who were not undergoing dialysis.

Future studies should focus on subgroups of patients with Crohn’s disease treated with ustekinumab.

The majority of drugs in development for IBD target inflammation.

About 30% of patients with ulcerative colitis do not adequately respond to anti-TNF therapy.

Bowel wall thickness and hyperemia in the neo-terminal ileum and bowel wall hyperemia at the ileocolic anastomosis were the only IUS parameters linked to endoscopic recurrence.

Balloon dilation is considered the gold standard in treating the complications associated with Crohn’s disease.

More than 70% of both groups met the primary efficacy outcomes.

The biggest theme identified was patients seeking peer-support and information about CPF symptoms, treatments, diet, experimental therapies, natural remedies, and patients’ apprehension regarding treatments.

Anti-TNF agents often cause various side effects, including inflammation.

Children of mothers with IBD are also more likely to be underdeveloped in height and weight compared to the control group.

Immunomodulators, incomplete vaccination, and non-mRNA vaccination were associated with a higher risk of adverse events for patients with IBD.

The endomina system can be affixed to various testing standard endoscopies for a bendable therapeutic channel.

The Prevalence of inflammatory bowel disease is highest in the Western world.

More research is needed on how the various FODMAP diets impact the gut microbiota and IBD management.

There remains a paucity of data for very early onset pediatric IBD in the majority of countries.

Moderate to severe disease activity and extensive disease were considered independent risk factors for malnutrition in patients with IBD.

JAK inhibitors have been effective in treating the other form of inflammatory bowel disease, ulcerative colitis.

GI symptoms manifest in children with COVID-19 more than they do in adult patients.

Treatment failure occurred in 10% of the intensive treatment group compared to 28% in the standard treatment group

Eli Lilly and Company is expected to apply for a Biologics License Application in the first half of 2022.

Biologics account for significant healthcare-related costs for patients with either ulcerative colitis or Crohn’s disease.

Moderate weekly consumption of beer was marginally associated with a reduction in the risk of Crohn’s disease.

The treatment also has potential in Crohn's disease and rheumatoid arthritis.